Fiche centre
University of California Irvine
Orange — United States
Essais liés11clinical trials
VilleOrangelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06909214
Essais cliniques associés
11| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Irreversible Electroporation | Cancer | Non applicable | NCT04972097 | PRESERVE — Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue | COMPLETED |
| CABA-201 | Lupus | Phase 1/2 | NCT06121297 | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | RECRUITING |
| Amivantamab | Cancer | Phase 3 | NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | ACTIVE_NOT_RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 4 | NCT06909214 | ADAPT-EARLY — A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) | RECRUITING |
| HyperQureTM Renal Denervation (RDN) System: | Hypertension | Non applicable | NCT06526858 | Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension | RECRUITING |
| PREVENT ALL ALS Study | Sclérose latérale amyotrophique | À vérifier | NCT06581861 | PREVENT ALL ALS Study | RECRUITING |
| Telitacicept | Myasthénie | Phase 3 | NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | RECRUITING |
| CABA-201 | Myasthénie | Phase 1/2 | NCT06359041 | RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | RECRUITING |
| AOC-1020 | Myopathies | Phase 3 | NCT07038200 | FORTITUDE-3 — A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | RECRUITING |
| Clemizole HCl | Épilepsie | Phase 3 | NCT04462770 | ARGUS — A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | RECRUITING |
| Celecoxib | Sclérose latérale amyotrophique | Phase 2 | NCT00355576 | Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis | COMPLETED |